Conatus 6556-14: Emricasan for NASH and Severe Portal Hypertension - Clinical Trial
What is the Purpose of this Study?
We are doing this study to learn whether a drug called emricasan can lower portal hypertension in patients with NASH
Patients with non-alcoholic steatohepatitis (NASH) with portal high blood pressure who have participated in the IND-6556-14 study
Who Can Participate in the Study?
Adults 18-85 years of age who
- Have been diagnosed with Non Alcoholic Liver Cirrhosis
- Do not have cancer
- Are participating in the IND-6556-14 study
Contact the study team for more information
What is Involved?
If you choose to join the study, you will:
- Continue in the same study group you were assigned to in the first 24 week study
-- Continue taking either Emricasan (the study drug) or placebo, whichever you were randomized to in the first part of the study for another 24 week
- Come for study visits every 8 weeks for physical exams, questionnaires, imaging exams, and lab tests